CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← DiaMedica Therapeutics Inc. (DMAC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

DiaMedica Therapeutics Inc. (DMAC)

Pharmaceutical Preparations · market cap $400M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-12
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
DiaMedica Therapeutics (DMAC) is a 27-employee pharmaceutical company with a ~$471M market cap (~$8.74/share, ~53.9M shares). Our data lists its lead asset as recombinant human tissue kallikrein in Phase 3 for acute stroke, with DM199 in Phase 2 for kidney diseases. Our calendar shows an estimated Phase 3 event on 2026-12-15, which we rate 9/10 importance, and the balance sheet figures in our data look incomplete.
The catalyst path
  • 2026-11-12Earningsimp 5/10
  • 2026-12-15 (est.)Phase 3 · Recombinant human tissue kallikreinimp 9/10
Pipeline
AssetPhaseIndication
DM199Phase 2Kidney Diseases
Recombinant human tissue kallikreinPhase 3Acute Stroke
Price & technical context
3-month
+41.4%
6-month
+53.0%
12-month
+63.3%
52-wk range
$5.33–$10.77
vs 50-day MA
+20.2%
vs 200-day MA
+35.0%
Realized vol
61.0%
Max drawdown
-49.2%

Daily closes through 2026-11-10. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for DMAC (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.